Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

906 - A prospective multicenter, phase II trial (NAC-GA trial) to evaluate the effect of neoadjuvant nab-paclitaxel plus gemcitabine therapy on overall survival in patients with borderline resectable pancreatic cancer:

Date

09 Sep 2017

Session

Poster display session

Presenters

Ken-ichi Okada

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

K. Okada1, T. Shimokawa2, S. Hirono1, M. Kawai1, M. Miyazawa1, Y. Kitahata1, H. Yamaue1

Author affiliations

  • 1 Second Department Of Surgery, Wakayama Medical University, 641-8510 - Wakayama/JP
  • 2 Clinical Study Support Center, Wakayama Medical University, 641-8510 - Wakayama/JP
More

Resources

Abstract 906

Background

Overall survival after neoadjuvant therapy and surgery for Borderline resectable pancreatic carcinoma (BRPC) is recognized as a goal for a multidisciplinary approach.

Trial design

Objective: The NAC-GA trial was a prospective multicenter phase II trial and its implementation was planned for patients with BRPC defined as borderline by the National Comprehensive Cancer Network (Version 2.2016) to investigate improvement of overall survival after the first day of initial therapy. Endpoints: This clinical trial primarily evaluated the primary endpoint of overall survival time from the first day of protocol therapy. The secondary endpoints were recurrence-free survival from the first day of protocol therapy, safety of the protocol therapy (adverse effects), morbidity, response rate, disease control rate, preoperative/postoperative tumor marker (CA19-9, CEA), rate of normalization, reduction rate of SUVmax value on PET-CT, chemotherapeutic effect, resection rate, R0 resection rate, surgical data, overall morbidity rates, rate of patient undergo postoperative adjuvant therapy, dose intensity, quality of life regarding fatigue and malaise assessed by the questionnaire of FACIT-F, and peripheral sensory neuropathy (PSN) assessed by the questionnaire of FACT/GOG-NTX subscale (Version 4) and Patient Neurotoxicity Questionnaire (PNQ). Sixty patients were included in the study. Treatment Methods: Enrolled patients were administered a 30-min intravenous infusion of nab-paclitaxel at a dose of 125 mg/m2, followed by a 30-min intravenous infusion of gemcitabine at a dose of 1000 mg/m2, on days 1, 8 and 15 over a four-week period as one cycle of regimen. Even if the dose on day 8 was missed, the next dose was still administered on day 8 of the same cycle as originally scheduled. All patients were given one week of rest between two cycles. This regimen was repeated twice. In the absence of disease progression, patients would undergo planned pancreatectomy within eight weeks. Postoperative adjuvant therapy was unregulated in this study.

Clinical trial identification

UMIN Clinical Trials Registry (UMIN000024154) - ClinicalTrials.gov (NCT02926183)

Legal entity responsible for the study

Wakayama Medical University

Funding

Research fund was provided to the Wakayama Medical University by Taiho Pharmaceutical Co., Ltd, Tokyo, Japan under a research agreement.

Disclosure

K-I. Okada: Honoraria and research funding from Taiho Pharmaceutical Co. Ltd., Tokyo, Japan. T. Shimokawa, S. Hirono, M. Kawai, M. Miyazawa, Y. Kitahata: Research fund to Wakayama Medical University by Taiho Pharmaceutical Co., Ltd, Tokyo, Japan under a research agreement. H. Yamaue: Honoraria and research funding from Taiho Pharmaceutical Co. Ltd., Tokyo, Japan. Research fund to Wakayama Medical University by Taiho Pharmaceutical Co., Ltd, Tokyo, Japan under a research agreement.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.